X4 Pharmaceuticals (XFOR) Total Liabilities (2017 - 2025)

X4 Pharmaceuticals has reported Total Liabilities for 9 years, with the latest figure at $104.2 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 16.19% year-over-year to $104.2 million; the trailing twelve-month figure through Dec 2025 stood at $104.2 million (down 16.19% YoY), and the FY2025 full-year result was $104.2 million, down 16.19% from the prior year.
• Total Liabilities for Q4 2025 stood at $104.2 million, up from $101.9 million in the prior quarter.
• The five-year high for Total Liabilities was $124.3 million in Q4 2024, with the low at $49.9 million in Q1 2022.
• Historically, Total Liabilities has averaged $85.5 million across 5 years, with a median of $98.7 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities surged 107.8% — and 2025, when it declined 16.19%.
• X4 Pharmaceuticals' Total Liabilities stood at $52.8 million in 2021, then jumped by 54.53% to $81.5 million in 2022, then gained by 17.94% to $96.2 million in 2023, then gained by 29.26% to $124.3 million in 2024, then retreated by 16.19% to $104.2 million in 2025.
• The last three Total Liabilities figures came in at $104.2 million (Q4 2025), $101.9 million (Q3 2025), and $101.2 million (Q2 2025), per Business Quant data.